INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 143 filers reported holding INFINITY PHARMACEUTICALS INC in Q4 2014. The put-call ratio across all filers is 2.93 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $224,000 | +622.6% | 165,998 | +738.5% | 0.01% | +500.0% |
| Q3 2016 | $31,000 | -91.6% | 19,798 | -92.9% | 0.00% | -87.5% |
| Q2 2016 | $369,000 | +17.5% | 277,600 | +365.8% | 0.01% | 0.0% |
| Q1 2016 | $314,000 | +71.6% | 59,600 | +175.9% | 0.01% | +33.3% |
| Q3 2015 | $183,000 | -11.6% | 21,600 | +14.3% | 0.01% | 0.0% |
| Q2 2015 | $207,000 | -3.3% | 18,900 | +49.1% | 0.01% | -14.3% |
| Q4 2014 | $214,000 | -1.4% | 12,679 | -21.6% | 0.01% | -12.5% |
| Q3 2014 | $217,000 | -33.8% | 16,163 | -20.1% | 0.01% | -68.0% |
| Q2 2013 | $328,000 | – | 20,240 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,354,963 | $38,132,000 | 1.80% |
| Orbimed Advisors | 4,520,800 | $73,201,000 | 1.55% |
| QVT Financial LP | 1,326,610 | $21,480,000 | 1.44% |
| BB BIOTECH AG | 1,089,828 | $17,646,000 | 1.27% |
| Meditor Group Ltd | 250,000 | $4,048,000 | 0.55% |
| Perimeter Capital Partners, LLC | 159,915 | $2,589,000 | 0.50% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 156,808 | $2,539,000 | 0.43% |
| Broadfin Capital, LLC | 117,172 | $1,897,000 | 0.37% |
| OXFORD ASSET MANAGEMENT LLP | 811,331 | $13,184,000 | 0.36% |
| Baker Brothers Advisors | 1,016,433 | $16,458,000 | 0.33% |